Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
22 participants
INTERVENTIONAL
2013-10-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will be undertaken according to a double-blind, cross over, randomized, placebo controlled design and will be conducted at the Institute of Nutrition and Functional Foods (INAF) of Laval University. The study will involve a total of 20 healthy subjects (10 men and 10 women. Included subjects will undergo an 6-hour oral fat tolerance, on two separate occasions (one time following dietary supplement consumption and one time following consumption of a placebo). The two test days will be separated by maximum of two weeks. The outcomes are the changes in the plasma levels of inflammatory cytokines in their gene expression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Curcumin on Vascular Reactivity
NCT01543386
L-carnitine and Coenzyme Q10 in Relation to the Oxidative Stress, Antioxidant Enzymes Activities, Inflammation, and the Risk of Coronary Artery Disease
NCT01819701
Oral Curcumin Supplementation in Middle-Aged and Older Adults Improves Vascular Function
NCT01968564
Effect of Curcumin on Microvascular Response and Tissue Oxygenation
NCT04119752
Effect of Polyphenol Extract on Cardiovascular Health Markers: a 4 Way Randomised Crossover Study
NCT05220059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Resveratrol is a polyphenol that is found in berries, grapes and red wine among others. Interest for resveratrol as a health-promoting molecule has flourished in recent years as it has been shown to prevent co-morbidities associated with diabetes and CVD. Evidence of the physiological benefits of resveratrol in humans is somewhat limited, but nonetheless supports an antiinflammatory action.
There is also an increasing body of evidence supporting the role of curcumin, a polyphenol from the curcuminoid family, as a modulator of the inflammatory pathway.These observations underline the anti-inflammatory potential of curcumin and how it may serve in the prevention and treatment of chronic conditions like diabetes and CVD.
The general objective of this project is to investigate the acute effect of consuming dietary supplement combining resveratrol and curcumin on the inflammatory response following the consumption of a high-fat meal in healthy individuals with slightly elevated waist girth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Resveratrol, curcumin
Subjects will take 2 capsules of resveratrol and curcumin. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
Resveratrol, curcumin
Placebo
Subjects will take 2 capsules of Placebo. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resveratrol, curcumin
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* When applicable, menopause will be defined as the absence of menses for at least 1 year
* Weight stable (for at least three (3) months)
* Otherwise healthy individuals
* No medication
* Waist circumference \>=94 cm for men or \>=80 cm for women
* With one (and no more than one) of the following:
* triglycerides \>=1.7 mmol/L
* HDL-c \<=1.03 mmol/L for men and \<=1.29 mmol/L for women
* fasting glucose \>=5.6 mmol/L
* systolic blood pressure \>=130 or diastolic blood pressure \>=85 mmHg
Exclusion Criteria
* Aversion/intolerance to spice
* ≥ 3 risk factors for the metabolic syndrome (IDF)
* Fasting triglycerides \> 4 mmol/L
45 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Atrium Innovations
INDUSTRY
Laval University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Charles Couillard
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles Couillard, PhD
Role: PRINCIPAL_INVESTIGATOR
INAF - Université Laval
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute on Nutrition and Functional Foods (INAF), Laval University
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vors C, Couillard C, Paradis ME, Gigleux I, Marin J, Vohl MC, Couture P, Lamarche B. Supplementation with Resveratrol and Curcumin Does Not Affect the Inflammatory Response to a High-Fat Meal in Older Adults with Abdominal Obesity: A Randomized, Placebo-Controlled Crossover Trial. J Nutr. 2018 Mar 1;148(3):379-388. doi: 10.1093/jn/nxx072.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INAF-2013-023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.